{"preliminary_commentary":{"by_channel":{"x_thread":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT06498479","nct_id":"NCT06498479","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06498479. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive HS-20093 as an intravenous (IV) infusion at dose of 8.0 mg/kg on Day 1 of each 21-day cycle until a treatment discontinuation criterion is met as specified in the protocol.","label":"HS-20093","type":"EXPERIMENTAL"},{"description":"Participants will receive topotecan until a treatment discontinuation criterion is met as specified in the protocol.","label":"Topotecan","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-08-20","type":"ACTUAL"},"conditions":["Small Cell Lung Cancer"],"enrollment":{"count":461,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"HS-20093","otherNames":[],"type":"DRUG"},{"name":"Topotecan","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-16","lead_sponsor":"Hansoh BioMedical R&D Company","official_title":"ARTEMIS-008：A Multicenter, Randomized, Open-label, Phase 3 Study of HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2026-08-20","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall survival","timeFrame":"From the date of randomization to the date of death due to any cause; Up to approximately 4.5 years"}],"references":[],"start_date":{"date":"2024-07-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT06498479"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06498479"}